UTHRHealthcare · Drug Manufacturers - Specialty & GenericThe 15 Wall Street analysts covering United Therapeutics Corp. hold a median 12-month price target of $705 — +19.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 27 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores United Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (36): Analysts have, on balance, been cutting their forecasts.
Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on UTHR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +19.2% from it.
Of the 20 most recent actions, 5 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | RBC Capital | Maintains | Outperform | $708 → $697 |
| 19 Oct 2026 | Leerink Partners | Maintains | Outperform | $685 → $725 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $677 → $708 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 7 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | $515 → $566 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 1 Oct 2026 | BTIG | Upgrade | Buy | $728 |
| 1 Oct 2026 | BTIG | Upgrade | Buy | — |
| 24 Sept 2026 | Goldman Sachs | Initiates | Sell | — |
| 24 Sept 2026 | Goldman Sachs | Initiates | Sell | $321 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $704 → $677 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 23 July 2026 | JP Morgan | Maintains | Overweight | $685 → $687 |
| 23 July 2026 | JP Morgan | Maintains | Overweight | — |
| 10 July 2026 | B of A Securities | Maintains | Neutral | — |
| 10 July 2026 | B of A Securities | Maintains | Neutral | $620 → $613 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $701 → $704 |
| 7 May 2026 | RBC Capital | Maintains | Outperform | — |
| 7 May 2026 | Wells Fargo | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
UTHR appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, United Therapeutics Corp. returned +40.4% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 37% of US stocks
Cheaper than 16% of US stocks
Cheaper than 24% of US stocks
Cheaper than 23% of US stocks
Higher than 25% of US stocks
Higher than 45% of US stocks
Higher than 95% of US stocks
Higher than 93% of US stocks
Higher than 94% of US stocks
Higher than 80% of US stocks
Higher than 94% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
United Therapeutics Corp. has a market value of $25.4B and an enterprise value of $22.5B.
Revenue in the twelve months to 30 June 2026: $3.2B. The latest quarter shrank 1.9% year on year.
Net income over the same four quarters: $1.3B, a 41.6% net margin.
Diluted earnings per share, trailing twelve months: $27.95.
Free cash flow in the twelve months to 30 June 2026: $1.1B.
United Therapeutics Corp. spent $2.6B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 20.4×; forward P/E: 17.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
United Therapeutics Corp. employs 1,400 people — $2.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own United Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
United Therapeutics announced that its board authorized an additional share repurchase program of up to $2 billion, available through October 21, 2027.
Why it matters — The authorization outlines the company's approved capacity and timeframe for repurchasing common stock.
United Therapeutics said it will release its third-quarter 2026 financial results before market open on November 4, at approximately 6:30 a.m. Eastern Time. The company will host a public webcast that day at 9:00 a.m. Eastern Time.
Why it matters — UTHR watchers can note the scheduled date and times for the company’s quarterly results and webcast.
United Therapeutics announced the opening of its third Designated Pathogen-Free facility, the Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. The company said its first DPF facility opened in Christiansburg, Virginia, in 2024 to produce xenografts for ongoing clinical trials.
Why it matters — The opening expands United Therapeutics’ facilities for producing xenografts, a development relevant to its organ-manufacturing capabilities.
The FDA cleared United Therapeutics to proceed with the phase 2 SUMMIT clinical trial of treprostinil SMI in PH-COPD. The 16-week, double-blind study will evaluate safety and tolerability in approximately 40 patients.
Why it matters — The clearance allows UTHR to advance clinical evaluation of treprostinil SMI for PH-COPD.
Liquidia settled six legal disputes with United Therapeutics, with the agreement securing Yutrepia access for PAH patients while requiring $380.7 million in payments and limiting the drug’s label.
Why it matters — The settlement resolves multiple disputes with UTHR and sets financial and labeling terms affecting Yutrepia.
The 15 Wall Street analysts covering United Therapeutics Corp. have a median 12-month price target of $705, with estimates ranging from $368 to $850. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering United Therapeutics Corp., 11 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks United Therapeutics Corp. 81 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, United Therapeutics Corp. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +19.2% from the last close, and Ticker Nerd's factor model ranks United Therapeutics Corp. 81 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering United Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UTHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $368 to $850 over the next 12 months.
United Therapeutics Corp. returned +40.4% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for chronic and life-threatening conditions, with particular expertise in pulmonary arterial hypertension. Its current portfolio includes Tyvaso DPI and Tyvaso inhalation solution, Remodulin injection, Orenitram extended-release tablets, and Adcirca tablets, which address different treatment needs within pulmonary vascular disease.
The most recent item we track (Business Wire, 22 Oct 2026): "United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization". United Therapeutics announced that its board authorized an additional share repurchase program of up to $2 billion, available through October 21, 2027.
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for chronic and life-threatening conditions, with particular expertise in pulmonary arterial hypertension. Its current portfolio includes Tyvaso DPI and Tyvaso inhalation solution, Remodulin injection, Orenitram extended-release tablets, and Adcirca tablets, which address different treatment needs within pulmonary vascular disease. The company also markets Unituxin, a therapy used in the treatment of high-risk neuroblastoma. United Therapeutics combines pharmaceutical research, manufacturing, regulatory operations, and specialized commercial support to serve patients, healthcare professionals, hospitals, and specialty pharmacies. Its business is centered on rare and serious diseases where ongoing treatment and differentiated delivery methods are important, including inhaled, injectable, and oral formulations. The company also operates in regenerative medicine through technologies and programs related to organ transplantation and the development of organs suitable for clinical use. United Therapeutics Corporation therefore occupies a specialized role in biotechnology, linking innovative drug development with advanced approaches to address critical shortages in transplantable organs.
CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. · 1,400 employees · United States · https://www.unither.com
